VIEMED HEALTHCARE, INC.
No SEC Form 4 filings for $VMD in the last 30 days.
Viemed Healthcare (NASDAQ:VMD) reported Q2 updates on home respiratory and sleep therapies. Management cited improved ventilator patient growth and said PAP setups rose, with sleep patients up about 5% sequentially and 44% YoY. Equipment sales nearly doubled to $19M. Gross profit was $45M (57.7% margin). Full-year net revenue guidance raised to $314M-$320M and adjusted EBITDA to $64M-$68M.
Viemed Healthcare (NASDAQ:VMD) reported Q2 2026 results for the three and six months ended June 30, 2026 and updated 2026 guidance. Cash was $10.7M, working capital $6.1M, and it repaid $2.2M of a term loan. Net revenue guidance was raised at the low end; net capex is now 8.5% to 10.0% of net revenue.
VIEMED HEALTHCARE, INC. (VMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningsrelease.htm EX-99.1 Document VIEMED HEALTHCARE ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS Lafayette, Louisiana (August 3, 2026) Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national provider of technology-enabled, home-based hea
Over the past 7 days, alphai's AI scored 3 news stories mentioning VMD (VIEMED HEALTHCARE, INC.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent VMD coverage spans earnings, financial news and insider activity.
Guidance raise plus improving cash flow supports a near-term positive bias, but margin pressure from mix shift and operating investments tempers upside.
Guidance raise plus capex range tightening should support near-term earnings expectations and reduce uncertainty for 2H 2026.
Guidance raise plus record ventilator and PAP patient growth suggests improving operating leverage and cash generation into 2H26.
This is a pre-earnings setup with consensus numbers, setting expectations for the Aug 3 print.
Forward revenue range can stabilize expectations for an HME provider, but without earnings, margins, or contract detail it may not drive sustained re-rating.
alphai scores every news story that mentions VMD with an AI model for sentiment and relevance, and aggregates insider trades from VIEMED HEALTHCARE, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Viemed Healthcare (NASDAQ:VMD) reported Q2 updates on home respiratory and sleep therapies. Management cited improved ventilator patient growth and said PAP setups rose, with sleep patients up about 5% sequentially and 44% YoY. Equipment sales nearly doubled to $19M. Gross profit was $45M (57.7% margin). Full-year net revenue guidance raised to $314M-$320M and adjusted EBITDA to $64M-$68M.
6 min readViemed Healthcare (NASDAQ:VMD) reported Q2 2026 results for the three and six months ended June 30, 2026 and updated 2026 guidance. Cash was $10.7M, working capital $6.1M, and it repaid $2.2M of a term loan. Net revenue guidance was raised at the low end; net capex is now 8.5% to 10.0% of net revenue.
4 min readVIEMED HEALTHCARE, INC. (VMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningsrelease.htm EX-99.1 Document VIEMED HEALTHCARE ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS Lafayette, Louisiana (August 3, 2026) Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national provider of technology-enabled, home-based hea
6 min readViemed Healthcare, Inc. (VMD) is scheduled to report Q2 2026 earnings on Aug. 3 at 8:00 AM ET. The consensus outlook cited for Q2 2026 calls for revenue of $78.0 million and EPS of $0.12, with figures stated in USD.
1 min readBiotech stocks hit 52-week highs on July 14, 2026. Hemab Therapeutics (COAG) reached $42.03 after positive Phase 2 results for HMB-002 and launched HMB-003. Alamar Biosciences (ALMR) hit $29.43 on a U.S. university proteomics partnership. Progyny (PGNY) rose 4% to $32; 2026 revenue guidance $1.365B-$1.405B. 10x Genomics (TXG) closed $43.98; 2026 revenue $600M-$625M. Viemed (VMD) peaked $12.61; 2026 net revenue $312M-$320M.
5 min readFrazier William (Chief Medical Officer) sold 10,000 shares of VIEMED HEALTHCARE, INC. (VMD) at $11.72 ($0.12M total) on 2026-06-25.
2 min readSmokoff Timothy sold 20,000 shares of VIEMED HEALTHCARE, INC. (VMD) at an average of $11.50 ($11.41–$11.56, $0.23M total) across 5 trades on 2026-06-24.
2 min readViemed Healthcare (NASDAQ:VMD) President Michael Moore sold 40,232 shares of the company's stock valued at $370,536.72, reducing his ownership by 2.38%. This sale was part of a series of transactions including additional sales on March 18th and 20th. Following these insider sales, the company's shares traded down 5.5% on increased volume, even though Viemed Healthcare recently reported earnings that beat analyst estimates but slightly missed revenue projections.
3 min readViemed Healthcare (NASDAQ:VMD) President Michael Moore sold 31,570 shares of the company's stock on March 18th for approximately $297,389.40, reducing his ownership by 1.83%. This sale is part of a larger pattern of insider selling totaling 136,802 shares between March 18-20. The company's stock fell 5.5% to $8.71 on heavy volume, following recent mixed quarterly results and a "Hold" consensus rating from analysts, despite a "Strong-Buy" upgrade from one firm.
4 min readSegall Bryant & Hamill LLC has initiated a new position in Viemed Healthcare (NASDAQ:VMD), acquiring 289,446 shares valued at approximately $1.97 million during the third quarter, representing about 0.76% ownership. Viemed Healthcare previously beat EPS estimates but missed revenue expectations, and institutional investors now hold around 74.24% of the stock. Analyst ratings for VMD are currently mixed, with an average "Hold" rating.
2 min read
